期刊文献+

通心络胶囊对高血压患者的降压效果观察 被引量:5

Effect of the Tongxinluo capsule on primary hypertension
下载PDF
导出
摘要 目的:观察通心络胶囊对原发性高血压的降压效果并探讨可能的作用机理。方法:将60例高血压患者随机配对分为常规(卡托普利)降压治疗组及通心络胶囊治疗组,每组30例;同时收集30例健康人作为对照组。疗程结束后,观察治疗前后血压变化及血浆中内皮素(endothelin,ET)和一氧化氮(nitric oxide,NO)的变化。结果:①治疗后通心络组与常规组血压下降明显(P均<0.05),但二者之间无明显差异(P>0.05);②经通心络治疗后ET明显下降,NO明显升高(P均<0.05),但与常规组和对照组比较无统计学差异(P>0.05)。结论:通心络胶囊具有减少ET和增加NO的作用,是治疗原发性高血压的一种有效的降压药。 Objective: To observe the depressurization effect of the Tongxinluo capsule on primary hypertension. Methods: Sixty patients with primary hypertension were matched-paired and randomly divided into two groups: 30 in the routine group (RG) treated with captopril, and the other 30 in the Tongxinluo group (TG). At the same time 30 healthy humans were enrolled in the control group (CG). Blood pressure (BP), endothelin (ET) and nitric oxide (NO) were determined both before and after the one-month treatment. Results: (1) Both Captopril and the Tongxinluo Capsule had a statistically great depressurization effect( P 〈 0.05) ; (2) NO was increased and ET was decreased in the TG group ( P 〈 0.05). There was no significant difference among the three groups after treatment ( P 〉 0.05). Conclusion: The Tongxinluo capsule can protect the vascular endothelium by reducing ET and increasing NO and it is an effective medicine for primary hypertension.
出处 《山东大学学报(医学版)》 CAS 北大核心 2007年第8期855-857,共3页 Journal of Shandong University:Health Sciences
关键词 通心络胶囊 原发性高血压 内皮素 一氧化氮 Tongxinluo capsule Primary hypertension Endothelin Nitric oxide
  • 相关文献

参考文献7

二级参考文献19

  • 1张强,杨丽红,乔鹏,崔天祥.通心络治疗不稳定型心绞痛68例临床观察[J].中国基层医药,2004,11(9):1080-1081. 被引量:8
  • 2Antiplatelet Trialist's Collaboration.Collaborative over view of randomized trial of antiplatelet the therapy Ⅲ.Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients[J].BM J,1994,308 (6 923):235-246.
  • 3Antiplatelet Trialist's Collaboration.Collaborative over view of randomized trial of antiplatelet therapy Ⅰ:Prevention of death,myocardial in fraction,and stroke by prolonged antiplatelet therapy in various categories of patients[J].BMJ,1994,308(6 921):81-106.
  • 4Patrono C,Coller B,Dalen JE,et al.Platelet-active drugs:the relation ships among dose,effectiveness,and side effects[J].Chest,1998,114(5 Suppl):470-488.
  • 5Grotemeyer KH,Scharafinski HW,Husstedt IW.Two-year followup of aspirin responder and aspirin non responder.A pilot-study including 180 post-stroke patients[J].Thromb Res,1993,71 (5):397-403.
  • 6Helgason CM,Bolin KM,Hoff JA,et al.Development of aspirin resistance in persons with previous ischemic stroke[J].Stroke,1994,25(12):2 331-2 336.
  • 7Gum PA,Kottke-Marchant K,Poggio ED,et al.Profile and prevalance of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88(3):230-235.
  • 8Maclsaac AI, Thomas JD. Topoi EJ. Toward the quiescent coronary plaque[J].J Am Coil Cardial. 1993.22 : 1228-1241.
  • 9Steen DK, Ravn HB,Falk E. Insight into the pathophysiology of unstable coronary artery disease[J]. Am J Cardiol.1997.80(5A) :5-9.
  • 10Vogel RA, Corretd MC, Plotnlck GD.Changes in flow-mediated brachlal artery vasoactivihy wilh lowering of desirable cholesterol levels in healthy midder-aged men[J]. Am J Cardiol, 199677,37-40.

共引文献36

同被引文献102

引证文献5

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部